|
||
J. Exp. Med.,
Volume 189, Number 2, January 18, 1999 381-394
By



From * Centre National de la Recherche Scientifique, UPR 420, F-94801 Villejuif, France; The barrier function of mitochondrial membranes is perturbed early during the apoptotic process. Here we show that the mitochondria contain a caspase-like enzymatic activity cleaving
the caspase substrate Z-VAD.afc, in addition to three biological activities previously suggested
to participate in the apoptotic process: (a) cytochrome c; (b) an apoptosis-inducing factor (AIF)
which causes isolated nuclei to undergo apoptosis in vitro; and (c) a DNAse activity. All of
these factors, which are biochemically distinct, are released upon opening of the permeability
transition (PT) pore in a coordinate, Bcl-2-inhibitable fashion. Caspase inhibitors fully neutralize the Z-VAD.afc-cleaving activity, have a limited effect on the AIF activity, and have no effect at all on the DNase activities. Purification of proteins reacting with the biotinylated caspase
substrate Z-VAD, immunodetection, and immunodepletion experiments reveal the presence
of procaspase-2 and -9 in mitochondria. Upon induction of PT pore opening, these procaspases are released from purified mitochondria and become activated. Similarly, upon induction of apoptosis, both procaspases redistribute from the mitochondrion to the cytosol and are
processed to generate enzymatically active caspases. This redistribution is inhibited by Bcl-2.
Recombinant caspase-2 and -9 suffice to provoke full-blown apoptosis upon microinjection
into cells. Altogether, these data suggest that caspase-2 and -9 zymogens are essentially localized
in mitochondria and that the disruption of the outer mitochondrial membrane occurring early
during apoptosis may be critical for their subcellular redistribution and activation.
Unité de Biochimie Structurale, Institut Pasteur, F-75724 Paris Cedex 15, France; § Centre National de la Recherche Scientifique, UPRES-A6022, Université de Technologie de
Compiègne, F-60200 Compiègne, France; and
Unité d'Oncologie Virale, Institut Pasteur,
F-75724 Paris Cedex 15, France
This article has been cited by other articles:
| TABLE OF CONTENTS |
|